Geode Capital Management LLC Increases Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS)

Geode Capital Management LLC grew its stake in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 1.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,814,446 shares of the company’s stock after buying an additional 44,762 shares during the period. Geode Capital Management LLC’s holdings in Atossa Therapeutics were worth $4,278,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ATOS. Intech Investment Management LLC bought a new position in Atossa Therapeutics in the 3rd quarter worth about $29,000. XTX Topco Ltd purchased a new position in Atossa Therapeutics in the 2nd quarter worth approximately $29,000. SG Americas Securities LLC raised its position in Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after purchasing an additional 30,037 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in Atossa Therapeutics in the third quarter worth approximately $75,000. Finally, Rhumbline Advisers bought a new position in Atossa Therapeutics during the second quarter valued at approximately $161,000. 12.74% of the stock is owned by hedge funds and other institutional investors.

Atossa Therapeutics Stock Up 5.2 %

Shares of ATOS stock opened at $1.01 on Monday. Atossa Therapeutics, Inc. has a twelve month low of $0.77 and a twelve month high of $2.31. The stock has a market cap of $127.06 million, a price-to-earnings ratio of -4.59 and a beta of 1.26. The business’s fifty day moving average is $1.22 and its 200 day moving average is $1.30.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ATOS shares. Ascendiant Capital Markets increased their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th. StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Atossa Therapeutics in a research note on Thursday, December 12th.

Atossa Therapeutics Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.